FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W258004195> ?p ?o ?g. }

• W258004195 abstract "Abstract Background Dabigatran is a new oral anticoagulant that specifically and reversibly inhibits thrombin. Its predictable pharmacokinetics and pharmacodynamics allow for minimal monitoring. However, there is currently no specific antidote to reverse its anticoagulant effects. Instead, activated prothrombin complex concentrate (aPCC) or recombinant Factor VIIa (rFVIIa) has been used to stop bleeding complications in patients on dabigatran. Both were originally used to treat hemophilia patients with inhibitors. Currently, Factor Eight Inhibitor Bypass Activity (FEIBA) is the only clinically approved aPCC, which contains Factors II, IX, X, and VII in both active and non-active forms. In contrast, rFVIIa is a human recombinant protein which can initiate clotting via the tissue factor (TF) pathway. It has been controversial which of these hemostatic agents is more efficient at reversing the effect of dabigatran, as animal models have failed to yield consistent results. We hereby utilized a modified Hemoclot turbdity assay to determine the equivalent concentrations of FEIBA and rFVIIa that can reverse the anticoagulant effect of dabigatran. Methods A mixture was prepared by incubating normal pooled plasma (NPP) with 382 nM dabigatran and varying concentration of hemostatic agents (FEIBA or rFVIIa), in the absence or presence of TF (Thrombosel®). The mixture was diluted 1:8 in TSP buffer, from which a 50 µL-aliquot was then incubated with 100 µL of NPP at 37°C for 5 min. Clotting was initiated with 100 µL of another mixture containing 10 mM Ca2+ and 2.5 nM thrombin in TSP. Turbidity was measured at 350 nm using a SpectraMax Pro spectrophotometer at 37°C for 2 hr. Clotting time (CT) was defined as the time to reach half of the maximum turbidity. Results In this modified Hemoclot turbidity assay, the CT without dabigatran was 101 s and it linearly increased dependent on the dabigatran concentration up to 1500 nM. Dabigatran at 382 nM, the therapeutic plasma concentration, prolonged CT 5-fold to 505 s. Addition of 1 U/mL FEIBA reduced the CT approximately 35% to 328 s. The reversal effect of FEIBA plateaued at 2.5 U/mL to 5 U/mL because there was minimal further reduction in the CT even with 10 U/mL FEIBA. In contrast, rFVIIa at a therapeutic concentration of 50 nM barely reduced the CT by <10% to 469 s. The reversal effects of rFVIIa were drastically enhanced by the addition of extrinsic tissue factor. With TF at 1.5 pM, the rFVIIa reduced the CT to a level similarly achieved by 1 U/mL of FEIBA, but the CT could not be reduced further despite the concentration of rFVIIa increased 10-fold to 400 nM. Finally, although both FEIBA and rFVIIa/TF reached an eventual plateau in the reversal of dabigatran, none of them could lower the CT to the baseline level. Summary/Conclusions Our in vitro study shows that reversal of dabigatran by rFVIIa is dependent on the concentration of TF. Higher levels of TF augment the reversal effects of rFVIIa to the extents similarly achieved with FEIBA. The data may, in part, explain the inconsistency of results obtained from in vivo studies using various animal models to compare rFVIIa and FEIBA for the reversal of dabigatran. The circulating TF levels in vivo are much lower than the amount of TF used in this study, thus its availability in the microenvironment for hemostasis varies depending on the methods used to induce bleeding. The data in this study also explain the variable clinical efficacy of rFVIIa reported in the literature when it is used to reverse the bleeding complications in patients on dabigatran. Disclosures: No relevant conflicts of interest to declare." @default.
• W258004195 created "2016-06-24" @default.
• W258004195 creator A5055696031 @default.
• W258004195 creator A5061204126 @default.
• W258004195 creator A5070921634 @default.
• W258004195 creator A5076794588 @default.
• W258004195 creator A5081626248 @default.
• W258004195 creator A5085238726 @default.
• W258004195 date "2013-11-15" @default.
• W258004195 modified "2023-10-08" @default.
• W258004195 title "Reversal Of Dabigatran By Recombinant Factor VIIa Is Dependent On The Amount Of Tissue-Factor" @default.
• W258004195 doi "https://doi.org/10.1182/blood.v122.21.1149.1149" @default.
• W258004195 hasPublicationYear "2013" @default.
• W258004195 type Work @default.
• W258004195 sameAs 258004195 @default.
• W258004195 citedByCount "1" @default.
• W258004195 countsByYear W2580041952016 @default.
• W258004195 crossrefType "journal-article" @default.
• W258004195 hasAuthorship W258004195A5055696031 @default.
• W258004195 hasAuthorship W258004195A5061204126 @default.
• W258004195 hasAuthorship W258004195A5070921634 @default.
• W258004195 hasAuthorship W258004195A5076794588 @default.
• W258004195 hasAuthorship W258004195A5081626248 @default.
• W258004195 hasAuthorship W258004195A5085238726 @default.
• W258004195 hasConcept C104317684 @default.
• W258004195 hasConcept C111113717 @default.
• W258004195 hasConcept C112705442 @default.
• W258004195 hasConcept C126322002 @default.
• W258004195 hasConcept C141071460 @default.
• W258004195 hasConcept C185592680 @default.
• W258004195 hasConcept C186738567 @default.
• W258004195 hasConcept C2776301958 @default.
• W258004195 hasConcept C2777091921 @default.
• W258004195 hasConcept C2777292125 @default.
• W258004195 hasConcept C2777444498 @default.
• W258004195 hasConcept C2778205648 @default.
• W258004195 hasConcept C2778382381 @default.
• W258004195 hasConcept C2778810321 @default.
• W258004195 hasConcept C2778961111 @default.
• W258004195 hasConcept C2779161974 @default.
• W258004195 hasConcept C2779365888 @default.
• W258004195 hasConcept C2781221834 @default.
• W258004195 hasConcept C2908626413 @default.
• W258004195 hasConcept C29730261 @default.
• W258004195 hasConcept C2992139802 @default.
• W258004195 hasConcept C40767141 @default.
• W258004195 hasConcept C42219234 @default.
• W258004195 hasConcept C55493867 @default.
• W258004195 hasConcept C71924100 @default.
• W258004195 hasConcept C77171857 @default.
• W258004195 hasConcept C89560881 @default.
• W258004195 hasConcept C98274493 @default.
• W258004195 hasConceptScore W258004195C104317684 @default.
• W258004195 hasConceptScore W258004195C111113717 @default.
• W258004195 hasConceptScore W258004195C112705442 @default.
• W258004195 hasConceptScore W258004195C126322002 @default.
• W258004195 hasConceptScore W258004195C141071460 @default.
• W258004195 hasConceptScore W258004195C185592680 @default.
• W258004195 hasConceptScore W258004195C186738567 @default.
• W258004195 hasConceptScore W258004195C2776301958 @default.
• W258004195 hasConceptScore W258004195C2777091921 @default.
• W258004195 hasConceptScore W258004195C2777292125 @default.
• W258004195 hasConceptScore W258004195C2777444498 @default.
• W258004195 hasConceptScore W258004195C2778205648 @default.
• W258004195 hasConceptScore W258004195C2778382381 @default.
• W258004195 hasConceptScore W258004195C2778810321 @default.
• W258004195 hasConceptScore W258004195C2778961111 @default.
• W258004195 hasConceptScore W258004195C2779161974 @default.
• W258004195 hasConceptScore W258004195C2779365888 @default.
• W258004195 hasConceptScore W258004195C2781221834 @default.
• W258004195 hasConceptScore W258004195C2908626413 @default.
• W258004195 hasConceptScore W258004195C29730261 @default.
• W258004195 hasConceptScore W258004195C2992139802 @default.
• W258004195 hasConceptScore W258004195C40767141 @default.
• W258004195 hasConceptScore W258004195C42219234 @default.
• W258004195 hasConceptScore W258004195C55493867 @default.
• W258004195 hasConceptScore W258004195C71924100 @default.
• W258004195 hasConceptScore W258004195C77171857 @default.
• W258004195 hasConceptScore W258004195C89560881 @default.
• W258004195 hasConceptScore W258004195C98274493 @default.
• W258004195 hasLocation W2580041951 @default.
• W258004195 hasOpenAccess W258004195 @default.
• W258004195 hasPrimaryLocation W2580041951 @default.
• W258004195 hasRelatedWork W1965597681 @default.
• W258004195 hasRelatedWork W1979997504 @default.
• W258004195 hasRelatedWork W2022451762 @default.
• W258004195 hasRelatedWork W2055204447 @default.
• W258004195 hasRelatedWork W2055450420 @default.
• W258004195 hasRelatedWork W2080450517 @default.
• W258004195 hasRelatedWork W2109003412 @default.
• W258004195 hasRelatedWork W2115817481 @default.
• W258004195 hasRelatedWork W2313295171 @default.
• W258004195 hasRelatedWork W2535378072 @default.
• W258004195 hasRelatedWork W2551143014 @default.
• W258004195 hasRelatedWork W2562382626 @default.
• W258004195 hasRelatedWork W2564002174 @default.
• W258004195 hasRelatedWork W2564572717 @default.
• W258004195 hasRelatedWork W2565371370 @default.
• W258004195 hasRelatedWork W2573168360 @default.
• W258004195 hasRelatedWork W2591336682 @default.

• next